NCT04688931

Brief Summary

This global, randomized, controlled, open-label Phase 3 study was designed to assess the long-term efficacy and safety of UGN-102 (mitomycin) for intravesical solution with or without (±) transurethral resection of bladder tumors (TURBT) versus TURBT alone for the treatment of patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

Trial Health

68
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
282

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Feb 2021

Geographic Reach
10 countries

139 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 21, 2020

Completed
5 months until next milestone

First Posted

Study publicly available on registry

December 30, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

February 19, 2021

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 17, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 17, 2023

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

June 6, 2024

Completed
Last Updated

June 6, 2024

Status Verified

May 1, 2024

Enrollment Period

2.1 years

First QC Date

July 21, 2020

Results QC Date

May 7, 2024

Last Update Submit

May 7, 2024

Conditions

Keywords

Non-muscle invasive bladder cancerLow grade non-muscle invasive bladder cancerIntermediate risk non-muscle invasive bladder cancerNMIBCUGN-102MitomycinTransurethral resection of bladder tumorsTURBT

Outcome Measures

Primary Outcomes (1)

  • Disease-free Survival (DFS)

    DFS is defined as the time from randomization until the earliest date of any of the following events: failure to be rendered free of local disease at the 3-month Visit (TURBT arm only), recurrence of LG disease after the 3-month Visit (ie, during the Follow-up Period), progression to high-grade (HG) disease, or death due to any cause. Summarized is the Kaplan-Meier estimated probability of remaining event-free at 15 months from randomization.

    15 months

Secondary Outcomes (9)

  • Time to Recurrence (TTR)

    15 months

  • Complete Response Rate (CRR)

    3 months

  • Duration of Response (DOR)

    12 months

  • Observed CRR at Scheduled Disease Assessment Time Points

    12 months

  • Number of TURBTs

    3 months

  • +4 more secondary outcomes

Study Arms (2)

UGN-102 ± TURBT

EXPERIMENTAL

6 weekly intravesical instillations of UGN-102 (75 mg mitomycin) starting on Day 1 + TURBT for patients with NCR due to residual LG disease at the 3-month Visit (3 months after the start of treatment with UGN-102).

Drug: UGN-102Procedure: TURBT

TURBT Alone

ACTIVE COMPARATOR

TURBT on Day 1 + repeat TURBT for patients with NCR due to residual LG disease at the 3-month Visit (3 months after the initial TURBT).

Procedure: TURBT

Interventions

UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid under chilled conditions, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.

Also known as: UGN-102 (mitomycin) for intravesical solution
UGN-102 ± TURBT
TURBTPROCEDURE

The current standard of care for treatment of LG-IR-NMIBC is TURBT under general anesthesia.

Also known as: Transurethral resection of bladder tumors
TURBT AloneUGN-102 ± TURBT

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
  • Patient who has newly diagnosed or historic LG-NMIBC (Ta) histologically confirmed by cold cup biopsy at Screening or within 8 weeks of Screening.
  • Has intermediate risk disease, defined as having 1 or 2 of the following:
  • Presence of multiple tumors;
  • Solitary tumor \> 3 cm;
  • Recurrence (≥ 1 occurrence of LG-NMIBC within 1 year of the current diagnosis).
  • Negative voiding cytology for HG disease within 6 weeks of Screening.
  • Has adequate organ and bone marrow function as determined by the following routine laboratory tests:
  • Leukocytes ≥ 3,000 cells per μL;
  • Absolute neutrophil count ≥ 1,500 cells per μL;
  • Platelets ≥ 100,000 per μL;
  • Hemoglobin ≥ 9.0 g/dL;
  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN);
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN;
  • Alkaline phosphatase (ALP) ≤ 2.5 × ULN;
  • +3 more criteria

You may not qualify if:

  • History of carcinoma in situ (CIS) on preliminary cystoscopy within 5 years of enrollment.
  • Received Bacillus Calmette-Guérin (BCG) treatment for urothelial carcinoma (UC) within previous 1 year.
  • History of HG papillary UC in the past 2 years.
  • Known allergy or sensitivity to mitomycin that in the investigator's opinion cannot be readily managed.
  • Clinically significant urethral stricture that would preclude passage of a urethral catheter.
  • History of pelvic radiotherapy.
  • History of:
  • Neurogenic bladder;
  • Active urinary retention;
  • Any other condition that would prohibit normal voiding.
  • Past or current muscle invasive (ie, T2, T3, T4) or metastatic UC or concurrent upper tract UC.
  • Current tumor stage of T1.
  • Has an underlying substance abuse or psychiatric disorder such that, in the opinion of the investigator, the patient would be unable to comply with the protocol.
  • History of prior treatment with an intravesical chemotherapeutic agent except for a single dose of chemotherapy immediately after any previous TURBT.
  • Has previously participated in a study in which they received UGN-102.
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (139)

Arizona Institute of Urology, PLLC

Tucson, Arizona, 85704, United States

Location

Loma Linda University Medical Center

Loma Linda, California, 92350, United States

Location

Urology Group of Southern California

Los Angeles, California, 90017, United States

Location

San Diego Clinical Trials

San Diego, California, 92120, United States

Location

Providence Saint John's Health Center

Santa Monica, California, 90404, United States

Location

Skyline Urology

Sherman Oaks, California, 91411, United States

Location

University of Chicago Hospital

Chicago, Illinois, 60637, United States

Location

Comprehensive Urologic Care

Lake Barrington, Illinois, 60010, United States

Location

First Urology, PSC

Jeffersonville, Indiana, 47130, United States

Location

Wichita Urology Group

Wichita, Kansas, 67226, United States

Location

Regional Urology, LLC

Shreveport, Louisiana, 71106, United States

Location

Chesapeake Urology Research Associates

Baltimore, Maryland, 21204, United States

Location

Chesapeake Urology Research Associates

Hanover, Maryland, 21076, United States

Location

Adult & Pediatric Urology, PC

Omaha, Nebraska, 68114, United States

Location

Urology Center

Las Vegas, Nevada, 89144, United States

Location

New Jersey Urology

Bloomfield, New Jersey, 07003, United States

Location

New Jersey Urology

Englewood, New Jersey, 07631, United States

Location

Garden State Urology

Morristown, New Jersey, 07960, United States

Location

Albany Medical Center

Albany, New York, 12208, United States

Location

Great Lakes Physician dba WNY Urology Associates

Cheektowaga, New York, 14225, United States

Location

AccuMed Research Associates

Garden City, New York, 11530, United States

Location

Manhattan Medical Research

New York, New York, 10016, United States

Location

Stony Brook Cancer Center

Stony Brook, New York, 11794, United States

Location

Associated Medical Professionals of NY, PLLC

Syracuse, New York, 13210, United States

Location

UNC Chapel Hill Memorial Hospital

Chapel Hill, North Carolina, 27599, United States

Location

Clinical Research Solutions

Middleburg Heights, Ohio, 44130, United States

Location

Centers for Advanced Urology, LLP d.b.a Mid-Atlantic Urology

Bala-Cynwyd, Pennsylvania, 19004, United States

Location

Penn State Health Milton S. Hershey Medical Center and College of Medicine

Hershey, Pennsylvania, 17033, United States

Location

Fox Chase Cancer Center

Philadelphia, Pennsylvania, 19111, United States

Location

University of Pittsburgh

Pittsburgh, Pennsylvania, 15237, United States

Location

Carolina Urologic Research Center

Myrtle Beach, South Carolina, 29572, United States

Location

University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

Location

Urology San Antonio

San Antonio, Texas, 78229, United States

Location

Multiprofile Hospital for Active Treatment "Puls", Department of Urology

Blagoevgrad, 2700, Bulgaria

Location

Multiprofile Hospital for Active Treatment - Blagoevgrad

Blagoevgrad, 2700, Bulgaria

Location

Complex Oncology Center - Burgas

Burgas, 8000, Bulgaria

Location

Multiprofile Hospital for Active Treatment "Dr. Tota Venkova", Gabrovo, Department of Urology

Gabrovo, 5300, Bulgaria

Location

Multiprofile Hospital for Active Treatment "Sveti Nikolai Chudotvorets", Lom

Lom, 3600, Bulgaria

Location

Multiprofile Hospital for Active Treatment "City Clinic - Sveti Georgi"

Montana, 3400, Bulgaria

Location

University Multiprofile Hospital for Active Treatment "Dr. Georgi Stranski", Pleven, Urology Clinic

Pleven, 5800, Bulgaria

Location

University Multiprofile Hospital for Active Treatment "Sveta Marina" - Pleven, Department of Urology

Pleven, 5800, Bulgaria

Location

Multiprofile Hospital for Active Treatment Park Hospital

Plovdiv, 4000, Bulgaria

Location

University Multiprofile Hospital for Active Treatment "Sveti Georgi", Plovdiv, Clinic of Urology

Plovdiv, 4002, Bulgaria

Location

University Multiprofile Hospital for Active Treatment, Plovdiv, Department of Urology

Plovdiv, 4003, Bulgaria

Location

University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of Urology

Rousse, 7000, Bulgaria

Location

Multiprofile Hospital for Active Treatment - Shumen, Shumen, Department of Urology

Shumen, 9700, Bulgaria

Location

University Multiprofile Hospital for Active Treatment "Aleksandrovska", Sofia, Urology Clinic

Sofia, 1431, Bulgaria

Location

University Multiprofile Hospital for Active Treatment and Emergency Medicine "N.I. Pirogov", Sofia, Urology Clinic

Sofia, 1606, Bulgaria

Location

Multiprofile Hospital for Active Treatment - Targovishte

Targovishte, 7700, Bulgaria

Location

Multiprofile Hospital for Active Treatment, Varna part of Military Medical Academy, Clinic of Urology

Varna, 9000, Bulgaria

Location

Multiprofile Hospital for Active Treatment "Sveta Anna", Varna, Urology Clinic

Varna, 9002, Bulgaria

Location

University Multiprofile Hospital for Active Treatment "Sveta Marina"

Varna, 9010, Bulgaria

Location

Multiprofile Regional Hospital for Active Treatment "Dr. Stefan Cherkezov", Veliko Tarnovo, Department of Urology

Veliko Tarnovo, 5000, Bulgaria

Location

First Private Hospital Vratsa, Department of Urology

Vratsa, 3001, Bulgaria

Location

Multiprofile Hospital for Active Treatment "Sveti Pantaleymon", Yambol, Department of Urology

Yambol, 8600, Bulgaria

Location

East Viru Central Hospital, Surgery Clinic

Kohtla-Järve, 31025, Estonia

Location

East Tallinn Central Hospital Ltd., Surgery Clinic, Centre of Urology

Tallinn, 10138, Estonia

Location

West Tallinn Central Hospital Ltd., Department of Urology

Tallinn, 10617, Estonia

Location

North Estonia Medical Centre Foundation Ltd., Surgery Clinic, General and Oncology Urology Centre

Tallinn, 13419, Estonia

Location

Tartu University Hospital, Surgery Clinic, Department of Urology and Kidney Transplantation

Tartu, 50406, Estonia

Location

LTD Central University Clinic After Academic N. Kipshidze

Tbilisi, 0160, Georgia

Location

JSC Jerarsi, Department of Urology

Tbilisi, Georgia

Location

LTD Acad. F. Todua Medical Center - LTD Research Institute of Clinical Medicine, Clinical Research Department

Tbilisi, Georgia

Location

LTD Gidmedi, Urology Department

Tbilisi, Georgia

Location

LTD L. Managadze National Center of Urology, Department of Urology

Tbilisi, Georgia

Location

LTD MMT Hospital, Urology Department

Tbilisi, Georgia

Location

Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LTD, Department of Urology

Tbilisi, Georgia

Location

Pineo Medical Ecosystem Ltd., Department of Urology

Tbilisi, Georgia

Location

Tbilisi State Medical University and Ingorokva High Technology Medical Center University Clinic LTD, Urology Department

Tbilisi, Georgia

Location

Rambam Health Care Campus

Haifa, 31096, Israel

Location

Lady Davis Carmel Medical Center

Haifa, 3436212, Israel

Location

Edith Wolfson Medical Center

Holon, 58100, Israel

Location

Rabin Medical Center

Petah Tikva, 49100, Israel

Location

Chaim Sheba Medical Center

Ramat Gan, 5262000, Israel

Location

Liepajas Regional Hospital, Urology Department

Liepāja, LV-3414, Latvia

Location

P. Stradins Clinical University Hospital, Center for Urology

Riga, LV-1002, Latvia

Location

LLC Riga East University Hospital, Clinic of Urology and Oncologic Urology

Riga, LV-1038, Latvia

Location

Daugavpils Regional Hospital, Urology Department

Riga, LV-5417, Latvia

Location

Jan Biziel University Hospital #2 in Bydgoszcz, Teaching Department of Urology

Bydgoszcz, 85-168, Poland

Location

AKMED

Gliwice, 44-100, Poland

Location

Prof.E Michalowski Specialist Hospital

Katowice, 40-073, Poland

Location

SCM sp. z o.o. (LLC)

Krakow, 31-559, Poland

Location

"City Clinic" Limited Liability Company

Warsaw, 02-473, Poland

Location

Miedzyleski Specialist Hospital in Warsaw, Department of Urology

Warsaw, 04-749, Poland

Location

Krasnoyarsk A.I. Kryzhanovsky Regional Oncology Center

Krasnoyarsk, 660133, Russia

Location

D.D. Pletnyov City Clinical Hospital, Department of Oncourology

Moscow, 105077, Russia

Location

Moscow City Oncology Hospital #62

Moscow, 125130, Russia

Location

Murmansk Bayandin Regional Clinical Hospital

Murmansk, 183047, Russia

Location

Privolzhsky Regional Medical Center, Urology Department

Nizhny Novgorod, 603001, Russia

Location

Tsyb Medical Radiology Research Center, Oncourology Department

Obninsk, 249036, Russia

Location

Clinical Oncology Center, Department of Urology and Oncology

Omsk, 644013, Russia

Location

N.N. Burdenko Penza Regional Clinical Hospital, Department of Urology

Penza, 440026, Russia

Location

Pyatigorsk City Clinical Hospital, Department of Urology

Pyatigorsk, 357500, Russia

Location

Leningrad Regional Clinical Oncology Center, Department of Chemotherapy

Saint Petersburg, 188663, Russia

Location

Aleksandrovskaya City Hospital, Department of Urology

Saint Petersburg, 193312, Russia

Location

St. Petersburg Clinical Hospital under the Russian Academy of Sciences, Department of Urology

Saint Petersburg, 194017, Russia

Location

A.M. Nikiforov Russian Center for Emergency and Radiology Medicine, Department of Urology

Saint Petersburg, 194044, Russia

Location

St. Luka Clinical Hospital, Department of Urology

Saint Petersburg, 194044, Russia

Location

St.-Petersburg Scientific Research Institute of Phthisiopulmonology

Saint Petersburg, 194064, Russia

Location

Medical and Sanitary Unit #70 of "Passazhiravtotrans"

Saint Petersburg, 195009, Russia

Location

I.I. Mechnikov North-Western State Medical University, Department of Urology

Saint Petersburg, 195067, Russia

Location

Railway Clinical Hospital under OAO Russian Railways

Saint Petersburg, 195271, Russia

Location

First I.P. Pavlov State Medical University of St. Petersburg

Saint Petersburg, 197022, Russia

Location

N.N. Petrov National Medical Research Center of Oncology, Oncourology Department

Saint Petersburg, 197758, Russia

Location

City Hospital #15, Urology Department #12

Saint Petersburg, 198205, Russia

Location

Siberian State Medical University

Tomsk, 634050, Russia

Location

Regional Oncology Center, Tyumen, Oncology Department

Tyumen, 625041, Russia

Location

Republican Clinical Oncology Center

Ufa, 450054, Russia

Location

Volgograd Regional Center for Urology and Nephrology, Urology Department

Volzhskiy, 404120, Russia

Location

Medical Center for Diagnostics and Prevention Plus

Yaroslavl, 150040, Russia

Location

Sverdlovsk Regional Clinical Hospital #1

Yekaterinburg, 620102, Russia

Location

Clinical Center of Serbia, Clinic of Urology

Belgrade, 11000, Serbia

Location

Clinical Hospital Center Bezanijska Kosa, Clinic of Surgery, Department of Urology

Belgrade, 11080, Serbia

Location

Clinical Hospital Center Zemun, Urology unit

Belgrade, 11080, Serbia

Location

Clinical Center Kragujevac, Clinic of Urology, Nephrology and Dialysis

Kragujevac, 34000, Serbia

Location

Chernihiv Medical Center of Modern Oncology

Chernihiv, 14029, Ukraine

Location

Regional Communal Noncommercial Enterprise: Chernivtsi Regional Clinical Hospital

Chernivtsi, 58001, Ukraine

Location

Regional Municipal Non-commercial Enterprise "Chernivtsi Emergency Medical Hospital", Urology Department

Chernivtsi, 58023, Ukraine

Location

Public Enterprise "Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital" under Dnipropetrovsk Regional Council, Urology Department #2

Dnipro, 49005, Ukraine

Location

Public Non-Profit Enterprise "City Clinical Hospital #6" under Dnipro City Council, Department of Urology

Dnipro, 49074, Ukraine

Location

Public Non-Profit Enterprise "City Clinical Hospital #4" under Dnipro City Council, Department of Geriatric Urology Care

Dnipro, 49102, Ukraine

Location

Public Non-Profit Enterprise "Regional Clinical Hospital under Ivano-Frankivsk Regional Council", Department of Urology

Ivano-Frankivsk, 76008, Ukraine

Location

Prykarpattia Clinical Oncology Center under Ivano-Frankivsk Regional Council

Ivano-Frankivsk, 76018, Ukraine

Location

Public Non-Profit Enterprise under Kharkiv Regional Council "V.I. Shapoval Regional Medical Clinical Center for Urology and Nephrology", Urology Department #5

Kharkiv, 61037, Ukraine

Location

Communal Non-Profit Enterprise "Regional Center of Oncology", Department of Oncourology

Kharkiv, 61070, Ukraine

Location

Public Non-Profit Enterprise under Kharkiv Regional Council "Regional Clinical Specialized Center for Radiation Protection of Population", Department of Surgery

Kharkiv, 61166, Ukraine

Location

Communal non-commercial enterprise of Kherson regional council "Kherson regional oncological dispensary"

Kherson, 73000, Ukraine

Location

State Institution: Institute of Urology under the National Academy of Medical Sciences of Ukraine

Kyiv, 04053, Ukraine

Location

Volyn Regional Medical Oncology Centre

Lutsk, 43018, Ukraine

Location

Communal Noncommercial Enterprise of Lviv Regional Council "Lviv Regional Clinical Hospital", Department of Urology

Lviv, 79010, Ukraine

Location

Public Non-profit Enterprise under Lviv Regional Council: Lviv Regional Treatment and Diagnostics Oncology Center

Lviv, 79031, Ukraine

Location

Municipal Non-Profit Enterprise "Lviv Clinical Emergency Care Hospital", Department of Urology

Lviv, 79059, Ukraine

Location

Public Non-Profit Enterprise "Odesa Regional Clinical Hospital" under Odesa Regional Council

Odesa, 65025, Ukraine

Location

Public Non-Profit Enterprise "City Clinical Hospital #10" under Odesa City Council, Department of Urology and Nephrology

Odesa, 65074, Ukraine

Location

Sumy Regional Clinical Oncology Center

Sumy, 40022, Ukraine

Location

Public Non-Profit Enterprise Ternopil Regional Clinical Oncology Center, Department of Chemotherapy

Ternopil, 46023, Ukraine

Location

Municipal non-profit enterprise "Transcarpathian antitumor center" of the Transcarpathian Regional Council

Uzhhorod, 88014, Ukraine

Location

Communal Nonprofit Enterprise "Podilsky Regional Center of Oncology of Vinnytsia Regional Council"

Vinnytsia, 21029, Ukraine

Location

Municipal Nonprofit Enterprise: Zaporizhia Regional Clinical Hospital under Zaporizhia Regional Council, Department of Urology

Zaporizhia, 69600, Ukraine

Location

Related Publications (1)

  • Prasad SM, Huang WC, Shore ND, Hu B, Bjurlin M, Brown G, Genov P, Shishkov D, Khuskivadze A, Ganev T, Marchev D, Orlov I, Kopyltsov E, Zubarev V, Nosov A, Komlev D, Burger B, Raju S, Meads A, Schoenberg M. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 +/- Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). J Urol. 2023 Oct;210(4):619-629. doi: 10.1097/JU.0000000000003645. Epub 2023 Aug 7.

MeSH Terms

Conditions

Urinary Bladder NeoplasmsCarcinoma, Transitional CellNon-Muscle Invasive Bladder Neoplasms

Interventions

Mitomycin

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic Type

Intervention Hierarchy (Ancestors)

MitomycinsIndolequinonesQuinonesOrganic ChemicalsAzirinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Results Point of Contact

Title
Head of Clinical Development
Organization
UroGen Pharma

Study Officials

  • Sandip Prasad, MD

    Atlantic Health System

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2020

First Posted

December 30, 2020

Study Start

February 19, 2021

Primary Completion

March 17, 2023

Study Completion

March 17, 2023

Last Updated

June 6, 2024

Results First Posted

June 6, 2024

Record last verified: 2024-05

Locations